Search | Clinical Trials Finder

Conditions: Influenza, Human
Interventions: Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 33
States / cities: Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: COVID-19/ Flu A&B Rapid Panel; Device
Lead sponsor: Abbott Rapid Diagnostics Jena GmbH; Industry
Eligibility: Not listed
Enrollment: 2,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Influenza
Interventions: CAIV-T; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions: Aptitude Medical Systems Metrix COVID/Flu Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: 2 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts

Conditions: Influenza, Influenza A, Influenza B, COVID-19, Respiratory Syncytial Virus (RSV)
Interventions: ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content, No Intervention; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 17,043 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
Interventions: Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections; Diagnostic Test
Lead sponsor: Baebies, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions: artus Influenza A/B RT-PCR Test; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation; Drug · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: ARDS, Human, Covid19
Interventions: Longeveron Mesenchymal Stem Cells (LMSCs), Placebo; Biological · Other
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Subjects Possibly Exposed to COVID-19
Interventions: Not listed
Lead sponsor: Biocerna LLC; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fulton, Maryland

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 64 Years
Enrollment: 4,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more

Conditions: Influenza A, Influenza B
Interventions: QuickVue Influenza A+B; Device
Lead sponsor: Quidel Corporation; Industry
Eligibility: Not listed
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Rochester, New York • Belton, Texas + 2 more

Conditions: Influenza, Human
Interventions: Treatment Group Live Attenuated Flu Vaccine (LAIV); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza, Human, Influenza, Flu
Interventions: Diassess Influenza A and B Test; Device
Lead sponsor: Diassess Inc.; Industry
Eligibility: Not listed
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Inflammatory Bowel Diseases
Interventions: Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine; Biological
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, Human
Interventions: Flu Symptoms; Device
Lead sponsor: Sekisui Diagnostics, LLC; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Little Rock, Arkansas • Coral Gables, Florida • Lauderdale Lakes, Florida + 11 more

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Immunity, Cellular
Interventions: Influenza Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™ COVID-19/Flu A&B Panel; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 2 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Pelham, Alabama • Brooklyn, New York

Conditions: Influenza Type A, Influenza Type B, Influenza
Interventions: SAB-176, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza a, Influenza B, RSV, COVID 19
Interventions: LIAISON NES FLU A/B, RSV & COVID-19; Diagnostic Test
Lead sponsor: DiaSorin Molecular LLC; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Henderson, Nevada • Pittsburgh, Pennsylvania • McAllen, Texas

Conditions: PNAG-expressing Pathogenic Microbes Vaccine
Interventions: AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3, AV0328 - Cohort 4; Biological
Lead sponsor: Alopexx Vaccine, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Influenza, Human
Interventions: VRC-FLUDNA047-00-VP, Flulaval (Registered) Seasonal Influenza Vaccine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

Collection and Testing of Respiratory Samples

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

QuickVue Influenza A + B Test Field Study

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

Clinical Performance of the Diassess Influenza A and B Test

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

Assessment of the Clinical Performance of the ARROW-FLU System

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

T and B Cell Response to Avian Flu Vaccine

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

A Study of AV0328 Administered to Healthy Adult Volunteers

VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...